| Name | Title | Contact Details |
|---|
InB Biotechnologies Inc is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger`s pipeline includes preclinical NCEs from discovery as well repurposed clinical Rx agents shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.
Amlan International is the animal health business of Oil-Dri® Corporation of America, a leader in sorbent mineral technology. Amlan leverages Oil-Dri`s 80-plus years of mineral science expertise to develop proprietary, mineral-based feed additives that support optimal intestinal health while adding value for animal protein producers. The core of our feed additives is our natural mineral ingredient that contains high-capacity opal-CT lepispheres and undergoes proprietary thermal processing specifically tailored for each product. We also create synergistic blends of our mineral with other feed ingredients that further support normal gut function and digestive processes. Oil-Dri and the single-source mineral used in Amlan products are based in the USA, and because Amlan and Oil-Dri are vertically integrated, we control the quality, reliability, and safety of the mineral — from mine to feed bag. We do this by following sustainable mining practices and through the use of natural ingredients in our products. Our mineral-based feed additives meet the demands for cleaner food while reducing the inputs needed to raise production animals, helping to decrease the cost and environmental impact of poultry and livestock production. Leading integrators and producers worldwide trust our products to support animal intestinal health and add value to their operations. You can, too.
Active Motif is a fast-growing biotechnology company that is dedicated to developing new and innovative tools and techniques that help analyze nuclear function. Our employees are our biggest asset and our corporate policy is to treat them as such. This
Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world`s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.